Articles tagged "Kidney transplantation"

2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ B. Bone,² H. Wijeweera,² D. Brennan.²
¹Barnes-Jewish Hospital, St. Louis; ²Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…
2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2015 American Transplant Congress
Medication Adherence in Adolescents With Kidney Transplant and Chronic Kidney Disease: Patient/Caregiver Report Vs. Provider Perception
C. Pruette,¹ T. Brady,¹ S. Mendley,² B. Fivush,¹ S. Tuchman,³ A. Green,¹ M. Eakin,¹ K. Riekert.¹
¹Johns Hopkins University School of Medicine, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD; ³Children's National Medical Center, Washington, DC.
Background: Medication adherence in adolescent kidney transplant (KT) recipients is poor, with non-adherence (NA) ranging from 5-71%, and NA is associated with poor graft survival.…
2015 American Transplant Congress
Clinical Course of Pre-Existing Monoclonal Gammopathies Following Kidney Transplant
C. Johnson.
Nephrology, University of Washington, Seattle, WA.
INTRODUCTIONThe progression of monoclonal gammopathies following kidney transplant is not well described. Previous single-center retrospective data suggested that the course for a monoclonal gammopathy of…
2015 American Transplant Congress
HLA Broad Antigen and Eplet Mismatches in Determining the Risk of Acute Rejection After Kidney Transplantation
H. Do Nguyen,¹ W. Lim,^1,2 J. Chapman,³ J. Craig,^3,4 G. Wong.^3,4
¹School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia; ²Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; ³Nephrology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; ⁴School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Aim: To determine the clinical relevance of HLA-ABDR broad antigen and eplet matching for predicting acute rejection after kidney transplantation.Background: HLAMatchmaker determines structurally HLA compatibility…
2015 American Transplant Congress
Furthering the Link Between Ischemia and Immunity: Development of New Antibody Following Prolonged Delayed Graft Function
A. Gilbert,¹ E. Hall,¹ O. Timofeeva,² M. Awwad,² M. Grafals,¹ P. Weems,¹ D. Li,² S. Rosen-Bronson,² J. Moore,¹ B. Javaid,¹ M. Cooper.¹
¹Department of Surgery, MedStar Georgetown Transplant Institute, Washington, DC; ²Department of Pathology, MedStar Georgetown Transplant Institute, Washington, DC.
Introduction The purpose of this study is to examine the relationship between prolonged ischemia (delayed graft function - DGF) and the development of de novo…
2015 American Transplant Congress
Antibody-Mediated Rejection of Renal Allografts by CCR5-/- Mice Does Not Require CD8 T Cells
N. Kohei,¹ T. Tanaka,¹ H. Tsuda,¹ N. Dvorina,¹ K. Tanabe,² W. Baldwin,¹ R. Fairchild.¹
¹Immunology, Cleveland Clinic, Cleveland, OH; ²Urology, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
Antibody-mediated acute and chronic graft injury remains a major cause of renal allograft loss. Mechanisms underlying these injuries remain unclear due in part to the…
2015 American Transplant Congress
Steroid Free Immunosuppression Protocol in Pediatric Kidney Transplant Recipients Using Alemtuzumab: A Retrospective Single Center Study
R. Shah,¹ Z. Kadry,¹ S. Wassner,² D. Kees-Folts,² M. Freeman,² P. Freeman,¹ B. Olenowski,¹ A. Jain.¹
¹Surgery, Hershey Medical Center, Hershey, PA; ²Pediatric Nephrology, Hershey Medical Center, Hershey, PA.
Background: Steroid free immunosuppression is attractive in pediatric kidney transplantation (KTx). Aim of the present study is to examine the patient survival, graft survival, rate…
2015 American Transplant Congress
Kidney Double Negative TCR αβ + Cells: Newly Described Intra-Renal Kidney Lymphocytes That Respond to Ischemia Reperfusion in Mice
M. Martina,¹ S. Bandapalle,² S. Noel,² A. Saxena,¹ A. Hamad,¹ H. Rabb.²
¹Pathology, Johns Hopkins University, Baltimore, MD; ²Medicine, Johns Hopkins University, Baltimore, MD.
Background TCRαβ+CD4-CD8- double negative (DN) T cells with immunoregulatory function are a significant component of T cells residing in the kidney. The exact role of…
2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
C. Sommerer,¹ K. Budde,¹ V. Kliem,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ I. Hauser,¹ P. Reinke,¹ R. Stahl,¹ T. Rath,¹ M. Porstner,² D. Baeumer,² M. Zeier,¹ W. Arns,¹ F. Lehner.¹
¹Herakles Study Group, Germany; ²Novartis Pharma, Nuremberg, Germany; ³Herakles Study Group, Switzerland.
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…